ZTlido® treatment shows greater reductions in opioid use compared to 5% lidocaine patch in neuropathic pain patients.
Quiver AI Summary
Scilex Holding Company announced the publication of a study in Pain Medicine News revealing that patients treated with ZTlido® (lidocaine topical system 1.8%) showed a greater reduction in opioid use compared to those treated with the 5% lidocaine patch. In the study, 51.9% of ZTlido® patients experienced decreased or discontinued opioid use, compared to 45.5% with the 5% patch, with more ZTlido® patients reporting at least a 20% reduction in their opioid use (21.3% vs. 13.4%). While ZTlido® shows a non-significant increase in baseline opioid use (+3.1%), the 5% patch users saw a significant increase (+42.9%). The findings underscore the benefits of ZTlido® as a second-generation treatment for neuropathic pain, highlighting the effectiveness of advanced technology and adhesion.
Potential Positives
- ZTlido® has demonstrated a greater decrease or discontinuation of opioid use in patients compared to the 5% lidocaine patch, which may enhance its market appeal as a non-opioid pain management option.
- The study showed a significant proportion (21.3%) of ZTlido® patients achieved a 20% or greater reduction in opioid use, further highlighting its effectiveness in pain management.
- ZTlido® was associated with a non-significant change in opioid use, contrasting with the significant increase in opioid use (42.9%) observed in patients using the 5% patch, showcasing its potential advantages for patient safety and management.
- The publication of positive claims data in Pain Medicine News validates ZTlido®'s competitive edge in the market, potentially leading to increased interest from healthcare providers and patients.
Potential Negatives
- Patients on ZTlido® had a non-significant change in their baseline opioid use (+3.1%; P=0.146), which may indicate that while some patients decreased their usage, the overall impact on opioid reliance was minimal.
- The press release relies on retrospective claims data, which may raise questions about the robustness and reliability of the findings compared to prospective studies.
- Despite the positive claims data for ZTlido®, the significant increase in opioid use among patients using the 5% patch (+42.9%; P0.001) could overshadow the benefits of ZTlido® in a broader context, suggesting that the market acceptance might not be as strong as anticipated.
FAQ
What is ZTlido® and how does it compare to the 5% patch?
ZTlido® is a lidocaine topical system shown to reduce opioid use more effectively than the 5% lidocaine patch.
How many patients saw a decrease in opioid use with ZTlido®?
51.9% of patients treated with ZTlido® reported a decrease or discontinuation of opioid use.
What percentage of patients experienced a significant reduction in opioid use?
21.3% of patients in the ZTlido® group experienced a 20% or greater reduction in opioid use.
What was the change in opioid use for patients using the 5% patch?
Patients using the 5% patch experienced a significant increase in opioid use by 42.9% from baseline.
Where can I find more information about Scilex Holding Company?
Additional information about Scilex Holding Company can be found on their official website at www.scilexholding.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SCLX Insider Trading Activity
$SCLX insiders have traded $SCLX stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SCLX stock by insiders over the last 6 months:
- JAISIM SHAH (See Remarks) has traded it 3 times. They made 3 purchases, buying 92,000 shares and 0 sales.
- HENRY JI (Executive Chairperson) has traded it 2 times. They made 2 purchases, buying 18,888 shares and 0 sales.
- DORMAN FOLLOWWILL purchased 1,000 shares.
- JAY CHUN purchased 5,000 shares.
- DAVID LEMUS purchased 2,000 shares.
- YUE ALEXANDER WU purchased 20,000 shares.
- STEPHEN HOI MA (Chief Financial Officer) purchased 6,700 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SCLX Hedge Fund Activity
We have seen 31 institutional investors add shares of $SCLX stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 8,440,000 shares (-70.6%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 1,202,992 shares (+466.2%) to their portfolio in Q3 2024
- VANGUARD GROUP INC added 700,950 shares (+13.1%) to their portfolio in Q3 2024
- CITIGROUP INC added 479,630 shares (+577.3%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 437,558 shares (+275.9%) to their portfolio in Q3 2024
- LAURION CAPITAL MANAGEMENT LP removed 257,785 shares (-100.0%) from their portfolio in Q3 2024
- JANE STREET GROUP, LLC removed 247,271 shares (-89.1%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
More patients treated with ZTlido
®
saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%).
Of all study patients reporting a decrease in opioid use, significantly more in the ZTlido
®
group experienced a 20% or greater reduction in opioid use, compared with those treated with 5% lidocaine patch (21.3% vs. 13.4%; P=0.0008).
Patients on ZTlido
®
had a non-significant change in their baseline opioid use (+3.1%; P=0.146), while those using the 5% patch experienced a significant increase in opioid use from baseline (+42.9%; P<0.001).
PALO ALTO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease, today announced that Pain Medicine News published retrospective claims data on ZTlido
®
vs. lidocaine 5% patch.
Pain Medicine News, the premier trade publication in the pain management space, published decreased opioid utilization demonstrated with ZTlido
®
(lidocaine topical system 1.8%) in the magazine’s December edition. The article concluded that retrospective claims data showed that Scilex Pharmaceuticals’ flagship product, the branded ZTlido
®
lidocaine patch, was associated with less use of opioid analgesics in patients with neuropathic pain compared with the 5% lidocaine patch (generic). The researchers looked at claims with a diagnosis of neuropathic pain (postherpetic neuralgia, diabetic peripheral neuropathy or low back pain) in the Optum Claims database from May 1, 2018, to Sept. 30, 2023.
Among the key conclusions were that:
More patients treated with ZTlido
®
saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%).
Of all study patients reporting a decrease in opioid use, significantly more in the ZTlido
®
group experienced a 20% or greater reduction in opioid use, compared with those treated with 5% lidocaine patch (21.3% vs. 13.4%; P=0.0008).
Patients on ZTlido
®
had a non-significant change in their baseline opioid use (+3.1%; P=0.146), while those using the 5% patch experienced a significant increase in opioid use from baseline (+42.9%; P<0.001).
This study further affirms the difference between ZTlido
®
, as a second-generation lidocaine topical system, versus older, conventional lidocaine patches, and highlights the downstream impact conferred by advanced technology and improved adhesion. The full article may be accessed in the print edition of Pain Medicine News or online in the digital edition at this link:
December issue of
Pain Medicine News
For more information on Scilex Holding Company, refer to
www.scilexholding.com
For more information on Semnur Pharmaceuticals, Inc., refer to
www.semnurpharma.com
For more information on Scilex Holding Company Sustainability Report, refer to
www.scilexholding.com/investors/sustainability
For more information on ZTlido
®
including Full Prescribing Information, refer to
www.ztlido.com
.
For more information on ELYXYB
®
, including Full Prescribing Information, refer to
www.elyxyb.com
.
For more information on Gloperba
®
, including Full Prescribing Information, refer to
www.gloperba.com
.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido
®
(lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB
®
, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba
®
, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022.
Scilex Holding Company is headquartered in Palo Alto, California.
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. (“Semnur”) is a clinical-late stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.
Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California.
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Pain Medicine News published retrospective claims data on ZTlido
®
vs. lidocaine 5% patch.
Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the Board’s right to change the Record Date and/or revoke the Dividend; Scilex’s ability to consummate a joint venture or any other transaction with IPMC Company and develop and commercialize treatments for obesity, neurodegenerative, cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website:
www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido
®
is a registered trademark owned by Scilex Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba
®
is the subject of an exclusive, transferable license to Scilex Holding Company to use the registered trademark.
ELYXYB
®
is a registered trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2024 Scilex Holding Company All Rights Reserved.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
